Increased Radiosensitivity and Radiothermosensitivity of Human Pancreatic MIA PaCa-2 and U251 Glioblastoma Cell Lines Treated with the Novel Hsp90 Inhibitor NVP-HSP990

Overview

Journal Radiat Oncol

Publisher Biomed Central

Specialties Oncology
Radiology

Date 2013 Mar 2

PMID 23448094

Citations 22

Authors

Dusan Milanovic

Elke Firat

Anca Ligia Grosu

Gabriele Niedermann

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: Heat shock Protein 90 (Hsp90) is a molecular chaperone that folds, stabilizes, and functionally regulates many cellular proteins involved in oncogenic signaling and in the regulation of radiosensitivity. It is upregulated in response to stress such a heat. Hyperthermia is a potent radiosensitizer, but induction of Hsp90 may potentially limit its efficacy. Our aim was to investigate whether the new Hsp90 inhibitor NVP-HSP990 increases radiosensitivity, thermosensitivity and radiothermosensitivity of human tumor cell lines.

Material And Methods: U251 glioblastoma and MIA PaCa-2 pancreatic carcinoma cells were used. To determine clonogenic survival, colony forming assays were performed. Cell viability and proliferation were assesed by Trypan blue staining. Cell cycle and apoptosis analyses were performed by flow cytometry. DAPI staining was used to detect mitotic catastrophe.

Results: NVP-HSP990 increased the thermosensitivity, radiosensitivity and radio-thermosensitivity of both cell lines in clonogenic assays. 72 hours after irradiation with 4 Gy, a significant reduction in cell number associated with considerable G2/M acumulation and mitotic catastrophe as well as cell death by apoptosis/necrosis was observed.

Conclusions: Treatment with NVP-HSP990 strongly sensitized U251 and MIA PaCa-2 cells to hyperthermia and ionizing radiation or combination thereof through augmentation of G2/M arrest, mitotic catastrophe and associated apoptosis.

Citing Articles

Under lithium carbonate administration, nicotine triggers cell dysfunction in human glioblastoma U-251MG cells, which is distinct from cotinine.

Kato S Med Int (Lond). 2023; 2(3):19.

PMID: 36698501 PMC: 9829207. DOI: 10.3892/mi.2022.44.

Targeting Heat Shock Proteins in Malignant Brain Tumors: From Basic Research to Clinical Trials.

Babi A, Menlibayeva K, Bex T, Doskaliev A, Akshulakov S, Shevtsov M Cancers (Basel). 2022; 14(21).

PMID: 36358853 PMC: 9659111. DOI: 10.3390/cancers14215435.

Magnetic Fluid Hyperthermia as Treatment Option for Pancreatic Cancer Cells and Pancreatic Cancer Organoids.

Palzer J, Mues B, Goerg R, Aberle M, Rensen S, Olde Damink S Int J Nanomedicine. 2021; 16:2965-2981.

PMID: 33935496 PMC: 8079353. DOI: 10.2147/IJN.S288379.

Pharmacological Inhibition of HSP90 Radiosensitizes Head and Neck Squamous Cell Carcinoma Xenograft by Inhibition of DNA Damage Repair, Nucleotide Metabolism, and Radiation-Induced Tumor Vasculogenesis.

Naz S, Leiker A, Choudhuri R, Preston O, Sowers A, Gohain S Int J Radiat Oncol Biol Phys. 2021; 110(5):1295-1305.

PMID: 33838214 PMC: 8286306. DOI: 10.1016/j.ijrobp.2021.03.048.

Combined Photothermal and Ionizing Radiation Sensitization of Triple-Negative Breast Cancer Using Triangular Silver Nanoparticles.

Sears J, Swanner J, Fahrenholtz C, Snyder C, Rohde M, Levi-Polyachenko N Int J Nanomedicine. 2021; 16:851-865.

PMID: 33574666 PMC: 7872896. DOI: 10.2147/IJN.S296513.

References

Sekhar K, Sonar V, Muthusamy V, Sasi S, Laszlo A, Sawani J . Novel chemical enhancers of heat shock increase thermal radiosensitization through a mitotic catastrophe pathway. Cancer Res. 2007; 67(2):695-701. DOI: 10.1158/0008-5472.CAN-06-3212. View

Xiao Z, Chen Z, Gunasekera A, Sowin T, Rosenberg S, Fesik S . Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents. J Biol Chem. 2003; 278(24):21767-73. DOI: 10.1074/jbc.M300229200. View

Machida H, Matsumoto Y, Shirai M, Kubota N . Geldanamycin, an inhibitor of Hsp90, sensitizes human tumour cells to radiation. Int J Radiat Biol. 2004; 79(12):973-80. DOI: 10.1080/09553000310001626135. View

Overgaard J, Gonzalez Gonzalez D, Hulshof M, Arcangeli G, Dahl O, Mella O . Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology. Lancet. 1995; 345(8949):540-3. DOI: 10.1016/s0140-6736(95)90463-8. View

Wandinger S, Richter K, Buchner J . The Hsp90 chaperone machinery. J Biol Chem. 2008; 283(27):18473-7. DOI: 10.1074/jbc.R800007200. View

Trepel J, Mollapour M, Giaccone G, Neckers L . Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer. 2010; 10(8):537-49. PMC: 6778733. DOI: 10.1038/nrc2887. View

Vitale I, Galluzzi L, Castedo M, Kroemer G . Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol. 2011; 12(6):385-92. DOI: 10.1038/nrm3115. View

Bisht K, Bradbury C, Mattson D, Kaushal A, Sowers A, Markovina S . Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res. 2003; 63(24):8984-95. View

Bergs J, Franken N, Haveman J, Geijsen E, Crezee J, Van Bree C . Hyperthermia, cisplatin and radiation trimodality treatment: a promising cancer treatment? A review from preclinical studies to clinical application. Int J Hyperthermia. 2007; 23(4):329-41. DOI: 10.1080/02656730701378684. View

10.

Sakurai H, Kitamoto Y, Saitoh J, Nonaka T, Ishikawa H, Kiyohara H . Attenuation of chronic thermotolerance by KNK437, a benzylidene lactam compound, enhances thermal radiosensitization in mild temperature hyperthermia combined with low dose-rate irradiation. Int J Radiat Biol. 2005; 81(9):711-8. DOI: 10.1080/09553000500448172. View

11.

Frey B, Weiss E, Rubner Y, Wunderlich R, Ott O, Sauer R . Old and new facts about hyperthermia-induced modulations of the immune system. Int J Hyperthermia. 2012; 28(6):528-42. DOI: 10.3109/02656736.2012.677933. View

12.

Pirollo K, Hao Z, Rait A, Ho C, Chang E . Evidence supporting a signal transduction pathway leading to the radiation-resistant phenotype in human tumor cells. Biochem Biophys Res Commun. 1997; 230(1):196-201. DOI: 10.1006/bbrc.1996.5922. View

13.

Sapareto S, Raaphorst G, Dewey W . Cell killing and the sequencing of hyperthermia and radiation. Int J Radiat Oncol Biol Phys. 1979; 5(3):343-7. DOI: 10.1016/0360-3016(79)91214-8. View

14.

Horsman M, Overgaard J . Hyperthermia: a potent enhancer of radiotherapy. Clin Oncol (R Coll Radiol). 2007; 19(6):418-26. DOI: 10.1016/j.clon.2007.03.015. View

15.

Ohnishi K, Yokota S, Takahashi A, Ohnishi T . Induction of radiation resistance by a heat shock protein inhibitor, KNK437, in human glioblastoma cells. Int J Radiat Biol. 2006; 82(8):569-75. DOI: 10.1080/09553000600876645. View

16.

Dote H, Burgan W, Camphausen K, Tofilon P . Inhibition of hsp90 compromises the DNA damage response to radiation. Cancer Res. 2006; 66(18):9211-20. DOI: 10.1158/0008-5472.CAN-06-2181. View

17.

Krawczyk P, Eppink B, Essers J, Stap J, Rodermond H, Odijk H . Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition. Proc Natl Acad Sci U S A. 2011; 108(24):9851-6. PMC: 3116433. DOI: 10.1073/pnas.1101053108. View

18.

Gooljarsingh L, Fernandes C, Yan K, Zhang H, Grooms M, Johanson K . A biochemical rationale for the anticancer effects of Hsp90 inhibitors: slow, tight binding inhibition by geldanamycin and its analogues. Proc Natl Acad Sci U S A. 2006; 103(20):7625-30. PMC: 1458618. DOI: 10.1073/pnas.0602650103. View

19.

Wendtner C, Abdel-Rahman S, Krych M, Baumert J, Lindner L, Baur A . Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas. J Clin Oncol. 2002; 20(14):3156-64. DOI: 10.1200/JCO.2002.07.146. View

20.

Bull E, Dote H, Brady K, Burgan W, Carter D, Cerra M . Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin. Clin Cancer Res. 2004; 10(23):8077-84. DOI: 10.1158/1078-0432.CCR-04-1212. View